IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 42
- Registration Number
- NCT00891371
- Locations
- 🇧🇪
OLVZ Aalst, Aalst, Belgium
🇧🇪AZ Maria Middelares, Gent, Belgium
🇧🇪AZ Sint-Augustinus, Wilrijk, Belgium
Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
- Conditions
- Non Functioning Entero-pancreatic Endocrine Tumour
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 89
- Registration Number
- NCT00842348
- Locations
- 🇮🇹
Centro di Refierimiento Oncologica, Aviano, Italy
🇮🇹University of Naples, Naples, Italy
🇺🇸Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States
Factors Influencing Response to One BoNT-A Injection Cycle in Subjects Suffering From Idiopathic Cervical Dystonia
- Conditions
- Idiopathic Cervical Dystonia
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 404
- Registration Number
- NCT00833196
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, Australia
🇦🇺St Vincent's Hospital, Fitzroy, Australia
🇧🇪UZ Gent, Gent, Belgium
Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia
- Conditions
- Friedreich Ataxia
- Interventions
- Drug: EGb 761 120 mgDrug: Placebo
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 22
- Registration Number
- NCT00824512
- Locations
- 🇫🇷
Hospital Necker Enfants Malades, Paris, France
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
- Conditions
- Alzheimer's DiseaseCognitive Impairment
- Interventions
- Drug: PlaceboDrug: EGb761®
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 49
- Registration Number
- NCT00814346
- Locations
- 🇫🇷
Hôpital Corentin Celton 4 parvis Corentin Celton, Issy-Les-Moulineaux, France
🇫🇷Hôpital de Juvisy, Juvisy sur Orge, France
🇫🇷Observatoire de l'âge, Paris, France
BN83495 in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: BN83495 (Cohort 1)Drug: BN83495 (Cohort 2)Drug: BN83495 (Cohort 3)
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 17
- Registration Number
- NCT00790374
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸Johns Hopkins University Medical Center, Baltimore, Maryland, United States
🇺🇸Duke University Medical Center United States, Durham, North Carolina, United States
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 115
- Registration Number
- NCT00774930
- Locations
- 🇺🇸
VA Greater Los Angeles Health Care System, Los Angeles, California, United States
🇿🇦Westridge Medical Centre, Durban, South Africa
🇺🇦Medical Centre "Mriya", Kyiv, Ukraine
Non Interventional Post Marketing Programme in Neuroendocrine Tumours
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT00747786
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, United Kingdom
🇬🇧Aintree University Hospital, Liverpool, United Kingdom
🇬🇧Royal Free Hospital, London, United Kingdom
IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
- Conditions
- Primary Insulin-like Growth Factor-1 Deficiency
- Interventions
- Biological: mecasermin [rDNA origin] injection
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 1378
- Registration Number
- NCT00747604
- Locations
- 🇺🇸
Ipsen Central Contact, Basking Ridge, New Jersey, United States
Non Interventional Post Marketing Programme in Acromegaly
- Conditions
- Acromegaly
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 42
- Registration Number
- NCT00747500
- Locations
- 🇬🇧
University Hospital Coventry & Warwickshire, Coventry, United Kingdom
🇬🇧Aberdeen Royal Infirmary, Aberdeen, United Kingdom
🇬🇧Barnsley General Hospital, Barnsley, United Kingdom